Specification of Drug Substances and Products

Development and Validation of Analytical Methods
Herausgeber: Riley, Christopher M; Nguyen, K Lien

• Broschiertes Buch

Produktbeschreibung

Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Third Edition contains chapters discussing the unique requirements for the universal critical quality attributes, as well as the specific tests required to characterize and control different types of products, ranging in complexity from small molecules in immediate release oral dosage forms to complex products such as drug-antibody conjugates and mRNA-based products. This substantially expanded revision of the second edition will serve as practical comprehensive reference for scientists, managers, educators, and consultants involved in the development and regulation of pharmaceutical products.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science
• 3rd edition
• Seitenzahl: 908
• Erscheinungstermin: 25. September 2024
• Englisch
• Gewicht: 1000g
• ISBN-13: 9780443134661
• ISBN-10: 0443134669
• Artikelnr.: 69767800

Inhaltsangabe

Section I Introduction 1. Introduction Section II Regulatory considerations
and statistical approaches 2. Principles for setting specifications and
shelf lives 3. Stability studies: General regulatory considerations and
regional differences 4. Kinetics and mechanisms of drug degradation 5.
Analytical procedure life cycle management 6. Process analytical technology
7. Pharmacopeial methods and tests 8. Development of United States
Pharmacopeia-National Formulary (USPeNF) Monographs and General Chapters 9.
The distinctiveness of the British Pharmacopeia and its relationship to
other Pharmacopeia 10. Specifications and analytical procedures in
registration applications 11. Specifications and analytical proceduresin
clinical trial applications Section III Critical quality attributes 12.
Description and identification Ernest Parente 13. Assay and impurities:
Specifications of new chemical entities ("small molecules") 14. Assay and
impurities: Method development as part of analytical life-cycle management
15. Assay and impurities: Method validation 16. Mutagenic impurities 17.
Residual solvents 18. Elemental and inorganic impurities 19. Extractables
and leachables 20. Microbiology methods 21. Solid-state methods: An
overview 22. Solid-state characterization e Method development and
validation 23. Chiral methods 24. Water determination Section IV Dosage
forms and product types 25. Orally administered dosage forms 26. Drug
release: Topical products 27. Transdermal products 28. Inhalation products
29. Ophthalmic products 30. General analytical considerations for
parenteral products 31. Specification of biotechnology products including
cell and gene therapy 32. Biotechnology products: Validation of analytical
methods 33. Biosimilars 34. Antibody-drug conjugates 35. Oligonucleotides
36. Specifications for vaccines 37. Nanoparticle suspension dosage forms by
nanomilling 38. Development of connected drug delivery systems Section V
Biological fluids 39. Bioanalysis of biological matrix samples using liquid
chromatography-tandem mass spectrometry detection 40. Bioanalysis of
oligonuceotides